These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12186624)

  • 1. An evaluation of bicalutamide in the treatment of prostate cancer.
    Schellhammer PF
    Expert Opin Pharmacother; 2002 Sep; 3(9):1313-28. PubMed ID: 12186624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of bicalutamide in the treatment of prostate cancer.
    Schellhammer PF; Davis JW
    Clin Prostate Cancer; 2004 Mar; 2(4):213-9. PubMed ID: 15072604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
    Kolvenbag GJ; Blackledge GR; Gotting-Smith K
    Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA; Tyrrell CJ;
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bicalutamide dosages used in the treatment of prostate cancer.
    Kolvenbag GJ; Nash A
    Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
    Abrahamsson PA
    Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ; Iversen P; Newling DW
    Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogen monotherapy: indications and results.
    Iversen P
    Urology; 2002 Sep; 60(3 Suppl 1):64-71. PubMed ID: 12231053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicalutamide in advanced prostate cancer. A review.
    Goa KL; Spencer CM
    Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicalutamide (Casodex) in the treatment of prostate cancer.
    Fradet Y
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):37-48. PubMed ID: 14748655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
    Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
    Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antiandrogen monotherapy in the treatment of prostate cancer.
    Anderson J
    BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
    Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
    Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
    Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
    See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
    J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.